Related Experiment Videos

The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma

S Fulda1

  • 1University Children's Hospital, Ulm, Germany. simone.fulda@uniklinik-ulm.de

Current Cancer Drug Targets
|September 17, 2009
PubMed

Insights

Targeting the PI3K/Akt/mTOR pathway, crucial for cancer cell survival, shows promise for neuroblastoma treatment. Further research will determine the best therapeutic strategies for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol 3'-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key survival signaling cascade frequently dysregulated in various human cancers.
  • Pathological activation of Akt is commonly observed in neuroblastoma, correlating with unfavorable patient prognosis.
  • Targeting the PI3K/Akt/mTOR pathway represents a potential strategy for developing novel molecular therapies for neuroblastoma.

Purpose of the Study:

  • To explore the therapeutic potential of targeting the PI3K/Akt/mTOR pathway in neuroblastoma.
  • To review existing strategies for interfering with PI3K/Akt/mTOR signaling.
  • To highlight the need for future studies to identify optimal therapeutic agents for neuroblastoma.

Main Methods:

  • Review of current literature on PI3K/Akt/mTOR pathway signaling in cancer, with a focus on neuroblastoma.
  • Analysis of the correlation between Akt activation and prognosis in neuroblastoma.
  • Discussion of various strategies developed to target different components of the PI3K/Akt/mTOR cascade.

Main Results:

  • Aberrant activation of the PI3K/Akt/mTOR pathway is a common feature in neuroblastoma and is linked to poor outcomes.
  • Several therapeutic strategies targeting the PI3K/Akt/mTOR pathway have been developed.
  • The efficacy of these targeted agents in neuroblastoma treatment requires further investigation.

Conclusions:

  • Targeting the PI3K/Akt/mTOR pathway offers a promising avenue for molecularly targeted therapies in neuroblastoma.
  • Future research is essential to identify the most effective PI3K/Akt/mTOR inhibitors for neuroblastoma treatment.
  • These targeted agents hold the potential to improve outcomes for neuroblastoma patients, particularly those with advanced disease.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...